1. Articles in category: Immune Therapy

    1-24 of 395 1 2 3 4 ... 15 16 17 »
    1. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PLoS Med. 2018 Jan;15(1):e1002497

      Authors: Srinivasan P, Wu X, Basu M, Rossi C, Sandler AD

      Read Full Article
      Mentions: PD-1
    2. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN

      Read Full Article
      Mentions: Antibody Treatment
    3. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma

      The monoclonal anti-GD2 antibody ch14.18/CHO in combination with IL-2 is active and effective in high-risk neuroblastoma (NB) patients. Here, we investigated the inflammatory response and treatment tolerance of long-term infusion (LTI) of ch14.18/CHO (10 × 10 mg/m2; 24 hr) in combination with subcutaneous (s.c.) IL-2 in a single center program.

      Read Full Article
      Mentions: Antibody Treatment
    4. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.

      The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.

      Cancer Immunol Immunother. 2018 Jan 11;:

      Authors: Nguyen R, Houston J, Chan WK, Finkelstein D, Dyer MA

      Read Full Article
      Mentions: Antibody
    5. Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.

      Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.

      Biol Blood Marrow Transplant. 2018 Jan 04;:

      Authors: Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P

      Read Full Article
      Mentions: Refractory MYCN GvHD
    6. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

      Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

      Oncoimmunology. 2017;7(1):e1378843

      Authors: Bocca P, Carlo ED, Caruana I, Emionite L, Cilli M, De Angelis B, Quintarelli C, Pezzolo A, Raffaghello L, Morandi F, Locatelli F, Pistoia V, Prigione I

      Read Full Article
      Mentions: PD-1
    7. High-Affinity GD2-Specific Car T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

      High-Affinity GD2-Specific Car T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

      The GD2 ganglioside, which is abundant on the surface of neuroblastoma cells, is targeted by an FDA-approved therapeutic monoclonal antibody and is an attractive tumor-associated antigen for cellular immunotherapy. Chimeric antigen receptor (CAR)–modified T cells can have potent antitumor activity in B-cell malignancies, and trials to harness this cytolytic activity toward GD2 in neuroblastoma are under way.

      Read Full Article
    8. Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in ...

      VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal ...

      Read Full Article
    9. Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Drugs Today (Barc). 2017 Sep;53(9):469-476

      Authors: Greenwood K, Foster JH

      Abstract Dinutuximab is a monoclonal antibody targeted at disialoganglioside (GD2), a tumor-associated antigen widely expressed in human neuroblastoma cells. The incorporation of dinutuximab into standard treatment regimens for patients with high-risk neuroblastoma has changed the landscape of neuroblastoma therapy.

      Read Full Article
      Mentions: Antibody Treatment
    10. The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.

      The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.

      Front Immunol. 2017;8:1640

      Authors: Le TP, Thai TH

      Abstract Research on adult cancer immunotherapy is proceeding at a rapid pace resulting in an impressive success rate exemplified by a few high profile cases. However, this momentum is not readily extended to pediatric immunotherapy, and it is not for lack of trying.

      Read Full Article
      Mentions: Immunotherapy
    11. MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

      MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

      Oncotarget. 2017 Nov 10;8(56):95293-95302

      Authors: Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV

      Read Full Article
      Mentions: Immunotherapy MYCN
    12. PD-L1, Inflammation, non-coding RNAs, and Neuroblastoma: Immuno-oncology Perspective.

      PD-L1, Inflammation, non-coding RNAs, and Neuroblastoma: Immuno-oncology Perspective.

      Semin Cancer Biol. 2017 Nov 28;:

      Authors: Nallasamy P, Chava S, Verma SS, Mishra S, Gorantla S, Coulter DW, Byrareddy SN, Batra SK, Gupta SC, Challagundla KB

      Abstract Neuroblastoma is the most common pediatric solid tumor of neural crest origin. The current treatment options for neuroblastoma produce severe side effects.

      Read Full Article
    13. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.

      Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.

      Biol Blood Marrow Transplant. 2017 Nov 27;:

      Authors: Nassin ML, Nicolaou E, Gurbuxani S, Cohn SL, Cunningham JM, LaBelle JL

      Read Full Article
      Mentions: Immunotherapy
    14. New developments in immunotherapy for pediatric solid tumors.

      New developments in immunotherapy for pediatric solid tumors.

      Curr Opin Pediatr. 2017 Nov 20;:

      Authors: Schultz LM, Majzner R, Davis KL, Mackall C

      Abstract PURPOSE OF REVIEW: Building upon preclinical advances, we are uncovering immunotherapy strategies that are translating into improved outcomes in tumor subsets. Advanced pediatric solid tumors carry poor prognoses and resultant robust efforts to apply immunotherapy advances to pediatric solid tumors are in progress.

      Read Full Article
      Mentions: Immunotherapy
    15. YmAbs Announces Closing of $30 Million Extension of Private Equity Placement

      NEW YORK--(BUSINESS WIRE)--Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that, further to its press release dated October 24, 2017, the Company has completed an extended closing of an additional $30 million in a private equity placement, adding institutional investors Sofinnova Ventures and Scopia Capital Management to its list of shareholders. Together, with the $50 million raised in the fi

      Read Full Article
      Mentions: Immunotherapy
    16. MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database.

      MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database.

      Front Immunol. 2017;8:1473

      Authors: Zhang P, Wu X, Basu M, Dong C, Zheng P, Liu Y, Sandler AD

      Abstract Purpose: RNA and DNA sequencing data are traditionally used to discern intrinsic cellular pathways in cancer pathogenesis, their utility for investigating the tumor microenvironment (TME) has not been fully explored.

      Read Full Article
      Mentions: MYCN
    17. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    18. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

      PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

      Oncoimmunology. 2017;6(10):e1343775

      Authors: Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN

      Abstract Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC).

      Read Full Article
    19. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      MAbs. 2017 Nov 09;:0

      Authors: Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN

      Read Full Article
    20. Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.

      Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.

      Sci Rep. 2017 Oct 25;7(1):14049

      Authors: Rigo V, Emionite L, Daga A, Astigiano S, Corrias MV, Quintarelli C, Locatelli F, Ferrini S, Croce M

      Read Full Article
      Mentions: Immunotherapy PD-1
    21. Immune Thrombocytopenia in a Child with Neuroblastoma.

      Immune Thrombocytopenia in a Child with Neuroblastoma.

      Case Rep Pediatr. 2017;2017:1329489

      Authors: Ikizoglu HT, Ayan I, Tokat F, Tecimer T, Topuzlu Tekant G

      Abstract Thrombocytopenia is a frequent finding in patients with solid tumors. It is usually caused by bone marrow infiltration or by myelosuppression due to anticancer therapy; however immune thrombocytopenia (ITP) associated with solid tumors is rare. Neuroblastoma is the most common extracranial solid tumor in children.

      Read Full Article
      Mentions: Bone Marrow
    22. YmAbs Raises $50 Million in Equity Financing

      NEW YORK--(BUSINESS WIRE)--Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that it has closed a private placement among HBM Healthcare Investments and its current shareholders, raising $50 million. YmAbs’ Founder, President and Head of Business Development and Strategy, Thomas Gad said, “We are very pleased to welcome HBM as a significant shareholder in YmAbs, together with our existing shareh

      Read Full Article
      Mentions: Immunotherapy
    23. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Pediatr Surg Int. 2017 Oct 10;:

      Authors: Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, Motohashi S

      Read Full Article
    1-24 of 395 1 2 3 4 ... 15 16 17 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) PD-1